LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / Genflow (LSE:GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024. Chairman's Statement It is with ...

The systemic regulation of metabolic dysfunction-associated liver disease remains poorly understood. In this issue, Hsiao et ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...

At a low, squat building in Springfield, Ohio, housing a Haitian community center, the FBI has arrived to investigate ...

all while not causing muscle loss. Its novel dual mechanism of action, in addition to its weight loss benefits, is promising within the obesity and MASH spaces. Key opinion leaders interviewed by ...

The studies for overweight or obesity and for MASH therefore prove that this GCGR and GLP-1R dual agonist offers significant benefits in lowering body weight while also promoting a reduction in blood ...

MASH patients with significant alcohol intake. These changes highlight issues like the term ‘fatty’ being regarded as a stigmatizing term that prevented patients from seeking appropriate ...